Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Use of an exploratory landmark analysis that extends 1-year after the final cut-off date of the pivotal trial
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Use of an exploratory landmark analysis that extends 1-year after the final cut-off date of the pivotal trial

Scheduled Pinned Locked Moved PAAB Q&A
5 Posts 2 Posters 420 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • U Offline
    U Offline
    user123
    wrote on last edited by
    #1

    This question relates to the use of updated data (published & peer-reviewed) from an exploratory landmark analysis that included data over 5 years (i.e., 1 year longer than the pivotal trial cut-off period of 4 years). It is essentially the same RCT, endpoints, patients, etc., but it incorporates an extra year of data (exploratory). Note that the data/stats are directionally consistent with the final analysis data, and the reason we want to use it is to include the most up-to-date statistics. I.e., no new inferences would be made and the updated stats would be used (HR, p values, relative risk reduction, etc.). Is this permitted in a promotional context in HCP tools?

    Per provision 8 of the PAAB guidance document on KM analysis (https://www.paab.ca/resources/kaplan-meier/), unplanned, or otherwise exploratory, subsequent interim KM analyses can be used to update the KM curve, hazard ratio, and corresponding CI/p-values where a prior pre-planned interim analysis had already established statistical significance between study groups. This is similar to our case described above where we have an exploratory landmark analysis that extends 1 year beyond the final analysis and is directionally consistent with the statistically significant final analysis. Note that this is for an HCP-targeted tool.

    Jennifer CarrollJ 1 Reply Last reply
    0
    • U user123

      This question relates to the use of updated data (published & peer-reviewed) from an exploratory landmark analysis that included data over 5 years (i.e., 1 year longer than the pivotal trial cut-off period of 4 years). It is essentially the same RCT, endpoints, patients, etc., but it incorporates an extra year of data (exploratory). Note that the data/stats are directionally consistent with the final analysis data, and the reason we want to use it is to include the most up-to-date statistics. I.e., no new inferences would be made and the updated stats would be used (HR, p values, relative risk reduction, etc.). Is this permitted in a promotional context in HCP tools?

      Per provision 8 of the PAAB guidance document on KM analysis (https://www.paab.ca/resources/kaplan-meier/), unplanned, or otherwise exploratory, subsequent interim KM analyses can be used to update the KM curve, hazard ratio, and corresponding CI/p-values where a prior pre-planned interim analysis had already established statistical significance between study groups. This is similar to our case described above where we have an exploratory landmark analysis that extends 1 year beyond the final analysis and is directionally consistent with the statistically significant final analysis. Note that this is for an HCP-targeted tool.

      Jennifer CarrollJ Offline
      Jennifer CarrollJ Offline
      Jennifer Carroll
      wrote on last edited by
      #2

      Hi @user123

      This is a very specific question for an extension study. As we require the published study and original protocol for assessment, we suggest submitting for an opinion.

      U 1 Reply Last reply
      0
      • Jennifer CarrollJ Jennifer Carroll

        Hi @user123

        This is a very specific question for an extension study. As we require the published study and original protocol for assessment, we suggest submitting for an opinion.

        U Offline
        U Offline
        user123
        wrote on last edited by
        #3

        @jennifer-carroll noted! More generally speaking, would PAAB ever consider unplanned, exploratory long-term data in HCP promotional materials if the study population and results aligned with the final analysis trial data in the PM?

        Any additional insights you could provide would be much appreciated.

        Jennifer CarrollJ 1 Reply Last reply
        0
        • U user123

          @jennifer-carroll noted! More generally speaking, would PAAB ever consider unplanned, exploratory long-term data in HCP promotional materials if the study population and results aligned with the final analysis trial data in the PM?

          Any additional insights you could provide would be much appreciated.

          Jennifer CarrollJ Offline
          Jennifer CarrollJ Offline
          Jennifer Carroll
          wrote on last edited by
          #4

          Hi @user123

          PAAB has considered pre-planned, exploratory, long term data in HCP promotional materials. Pre-planning is a requirement per our study duration guidance document. The nature of the claims, i.e. promotional or claim neutral, would be determined by the protocol, original study, the published extension and statistical analysis. We hope that helps.

          U 1 Reply Last reply
          0
          • Jennifer CarrollJ Jennifer Carroll

            Hi @user123

            PAAB has considered pre-planned, exploratory, long term data in HCP promotional materials. Pre-planning is a requirement per our study duration guidance document. The nature of the claims, i.e. promotional or claim neutral, would be determined by the protocol, original study, the published extension and statistical analysis. We hope that helps.

            U Offline
            U Offline
            user123
            wrote on last edited by
            #5

            @jennifer-carroll thank you for clarifying! That's very helpful.

            1 Reply Last reply
            0
            Reply
            • Reply as topic
            Log in to reply
            • Oldest to Newest
            • Newest to Oldest
            • Most Votes


            • Login

            • Don't have an account? Register

            • Login or register to search.
            • First post
              Last post
            0
            • Categories
            • Recent
            • Tags
            • Popular
            • Users
            • Groups